Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13254MR)

This product GTTS-WQ13254MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13254MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2666MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ8549MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ4899MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ10220MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ14070MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ9444MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ6412MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ5114MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW